Published in Brain on May 12, 2008
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol (2009) 1.42
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol (2009) 1.18
Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis (2012) 1.16
AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci U S A (2008) 1.13
The innate immune system in demyelinating disease. Immunol Rev (2012) 1.10
Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 1.10
Targeting BAFF in autoimmunity. Curr Opin Immunol (2010) 1.08
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol (2010) 1.07
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci (2011) 1.06
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord (2012) 1.03
Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol (2012) 0.95
B-cell activating factor targeted therapy and lupus. Arthritis Res Ther (2012) 0.92
Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons? Front Immunol (2013) 0.92
Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. Neurotherapeutics (2016) 0.90
Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol (2012) 0.88
IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol (2015) 0.87
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev (2012) 0.86
Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations. Neurol Neuroimmunol Neuroinflamm (2016) 0.83
The Expression of BAFF Is Controlled by IRF Transcription Factors. J Immunol (2015) 0.83
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol (2015) 0.81
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS One (2015) 0.81
Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol (2014) 0.80
Fingolimod induces neuroprotective factors in human astrocytes. J Neuroinflammation (2015) 0.80
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics (2016) 0.80
Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis. PLoS One (2014) 0.78
Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord. PLoS One (2016) 0.78
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77
Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Sci Rep (2016) 0.76
Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes (2013) 0.76
Interferon-β1b increases Th2 response in neuromyelitis optica. Int J Mol Sci (2012) 0.76
Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera. Mult Scler Int (2013) 0.76
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol (2016) 0.76
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. Sci Rep (2015) 0.75
Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission. Brain Behav (2017) 0.75
Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75
Initial Pattern of Optic Nerve Enhancement in Korean Patients with Unilateral Optic Neuritis. Korean J Ophthalmol (2017) 0.75
Regulation of human glia by multiple sclerosis disease modifying therapies. Semin Immunopathol (2015) 0.75
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 4.58
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med (2000) 3.84
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84
Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol (2000) 2.73
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int (2003) 2.07
[Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids]. Nervenarzt (1992) 1.93
The fight of viruses against apoptosis. Curr Opin Genet Dev (1998) 1.88
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology (2011) 1.75
Bidirectional growth of the E. coli chromosome. Nat New Biol (1973) 1.73
Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology (1999) 1.73
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology (2008) 1.72
TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology (2008) 1.63
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis (2000) 1.58
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int (2005) 1.52
Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest (2005) 1.50
Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol (1995) 1.50
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain (2000) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
[Pregnancy and immunomodulatory therapy in multiple sclerosis patients]. Nervenarzt (2006) 1.45
Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain (1998) 1.41
Human myoblasts as antigen-presenting cells. J Immunol (1992) 1.39
Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis (2001) 1.34
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology (2011) 1.31
Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 1.30
Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest (1996) 1.24
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol (2007) 1.23
Neuro-immune crosstalk in CNS diseases. Neuroscience (2008) 1.22
HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet (1986) 1.16
Signaling lymphocytic activation molecule is expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta. J Immunol (2001) 1.16
Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis. Ann N Y Acad Sci (1981) 1.14
Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest (1997) 1.14
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 1.14
Association between nonspecific bronchial hyperreactivity and superoxide anion production by polymorphonuclear leukocytes in chronic air-flow obstruction. Am Rev Respir Dis (1988) 1.13
BK virus encephalitis in an immunocompetent patient. Arch Neurol (1996) 1.13
Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. Brain Pathol (2001) 1.13
Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology (1996) 1.12
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int (2003) 1.11
Transformation of human T-cell clones by Herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells. Proc Natl Acad Sci U S A (1993) 1.08
Antiapoptotic activity of the herpesvirus saimiri-encoded Bcl-2 homolog: stabilization of mitochondria and inhibition of caspase-3-like activity. J Virol (1998) 1.06
T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med (1995) 1.04
Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology (1986) 1.04
Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. Proc Natl Acad Sci U S A (1987) 1.04
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int (2005) 1.03
Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain (2001) 1.03
Immortalization of human T cells by Herpesvirus saimiri. Immunol Today (1995) 1.03
Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol (2003) 1.03
The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol (2001) 1.03
Functional phenotype of transformed human alphabeta and gammadelta T cells determined by different subgroup C strains of herpesvirus Saimiri. J Virol (1997) 1.02
Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol (1993) 1.02
Autoaggressive myocytotoxic T lymphocytes expressing an unusual gamma/delta T cell receptor. J Exp Med (1992) 1.01
[Multimodal group therapy for the elderly with chronic pain: concept and results in a before and after comparison]. Schmerz (2008) 1.00
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain (2009) 0.99
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int (2003) 0.99
Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain (2001) 0.99
Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol (1985) 0.98
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther (1987) 0.98
FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis. Br J Dermatol (2012) 0.97
The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology (1995) 0.97
Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes. Eur J Immunol (1992) 0.97
Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf (2001) 0.97
The recognition, diagnosis and management of cerebral vasculitis: a European survey. Eur J Neurol (2002) 0.96
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab (2001) 0.96
Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett (1994) 0.95
Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. Eur J Immunol (1993) 0.95
Multiple sclerosis. Immunomodulatory effects of human astrocytes on T cells. Brain (1994) 0.94
Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain (1999) 0.93
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand (2013) 0.93
Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol (2000) 0.92
Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology (2008) 0.92
RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet (2003) 0.92
Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain (1997) 0.92